+ Larger Font | - Smaller Font
Share


Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release Investigational Epcoritamab Duobody® Cd3xcd20 Combination Therapy Demonstrates High Response Rates In Clinical Trial Of Patients With Relapsed Or Refractory R R Follicular Lymphoma Fl is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.
Search RobinsPost News & Noticias


Press Release Investigational Epcoritamab Duobody%c2%ae Cd3xcd20 Combination Therapy Demonstrates High Response Rates In Clinical Trial Of Patients With Relapsed Or Refractory R R Follicular Lymphoma Fl | RobinsPost News & Noticias

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma ...


COPENHAGEN, Denmark--(BUSINESS WIRE)-- Genmab A/S (Nasdaq: GMAB) today announced new results from the Phase 1b/2 EPCORE® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging ... Read More

Epcoritamab Improves Outcomes, HRQOL in Patients With Relapsed/Refractory Follicular Lymphoma


Epcoritamab monotherapy achieved high overall (84.6%) and complete response rates (67.1%) in relapsed/refractory follicular lymphoma patients with multiple prior therapies. Combination therapy with ... Read More

Epcoritamab Plus Chemoimmunotherapy Yields 87% Response Rate in R/R DLBCL; 65% Proceed to Transplant


Epcoritamab plus chemoimmunotherapy achieved an 87% overall response rate in relapsed/refractory DLBCL patients, with 65% achieving complete response. The regimen offers a potential bridge to ASCT or ... Read More

Genmab A/S (GMAB)’s Epcoritamab Delivers 95% Response in Lymphoma


We recently published 11 Best Cancer Stocks to Buy Right Now. Genmab A/S is placed ninth among the best cancer stocks. Genmab A/S (NASDAQ:GMAB), a Danish biotechnology leader, specializes in ... Read More

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with ...


Decision to submit based on a positive overall response rate (ORR) (p-value < 0.0001), one of the dual primary endpoints in the Phase 3 EPCORE ® FL-1 trial Full results from the trial will be ... Read More


Blow Us A Whistle


Comments (Whistles) Designed By Disqus